国金证券：首次覆盖康诺亚-B(02162)予“买入”评级目标价83.29港元

智通财经2025-12-25

智通财经APP获悉，国金证券发布研报称，康诺亚-B(02162)在研管线众多，核心产品司普奇拜单抗已获批上市，CM512（TSLP/IL-13双抗）目前拓展多个II期临床，授权AZ的CMG901有望2026年于美国递交NDA。早研布局多技术平台，管线有望逐步推进，后备力量充足。首次覆盖给予“买入”评级，目标价83.29港元。国金证券主要观点如下：深度布局差异化布局自免慢病和肿瘤赛道核心产品司普奇拜...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2594238125?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-25 14:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594238125","market":"fut","top_or_hot":-1,"title":"国金证券：首次覆盖康诺亚-B(02162)予“买入”评级 目标价83.29港元","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，国金证券发布研报称，康诺亚-B(02162)在研管线众多，核心产品司普奇拜单抗已获批上市，CM512（TSLP/IL-13双抗）目前拓展多个II期临床，授权AZ的CMG901有望2026年于美国递交NDA。早研布局多技术平台，管线有望逐步推进，后备力量充足。首次覆盖给予“买入”评级，目标价83.29港元。国金证券主要观点如下：深度布局差异化布局自免慢病和肿瘤赛道核心产品司普奇拜...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1385794.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>国金证券：首次覆盖康诺亚-B(02162)予“买入”评级 目标价83.29港元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n国金证券：首次覆盖康诺亚-B(02162)予“买入”评级 目标价83.29港元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-25 14:38 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1385794.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，国金证券发布研报称，康诺亚-B(02162)在研管线众多，核心产品司普奇拜单抗已获批上市，CM512（TSLP/IL-13双抗）目前拓展多个II期临床，授权AZ的CMG901有望2026年于美国递交NDA。早研布局多技术平台，管线有望逐步推进，后备力量充足。首次覆盖给予“买入”评级，目标价83.29港元。国金证券主要观点如下：深度布局差异化布局自免慢病和肿瘤赛道核心产品司普奇拜...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1385794.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1385794.html","article_id":"2594238125","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2594238125","pubTimestamp":1766644729,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，国金证券发布研报称，康诺亚-B在研管线众多，核心产品司普奇拜单抗已获批上市，CM512目前拓展多个II期临床，授权AZ的CMG901有望2026年于美国递交NDA。首次覆盖给予“买入”评级，目标价83.29港元。目前司普奇拜单抗已纳入2025年12月国家医保目录，预计26年初执行，进入医保后有望快速放量。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"Sinolink Securities: Covered Connoya-B (02162) with a \"buy\" rating for the first time, with a target price of HK $83.29","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":1.5},"content_text":"智通财经APP获悉，国金证券发布研报称，康诺亚-B(02162)在研管线众多，核心产品司普奇拜单抗已获批上市，CM512（TSLP/IL-13双抗）目前拓展多个II期临床，授权AZ的CMG901有望2026年于美国递交NDA。早研布局多技术平台，管线有望逐步推进，后备力量充足。首次覆盖给予“买入”评级，目标价83.29港元。国金证券主要观点如下：深度布局差异化布局自免慢病和肿瘤赛道核心产品司普奇拜单抗为首个国产IL-4R单抗，先发优势明显，26年医保执行后有望快速放量。IL-4R单抗可靶向特应性皮炎(AD)、慢性鼻窦炎伴鼻息肉(CRSwNP)等多种II型炎症反应性疾病，全球目前仅2款IL-4R单抗获批上市，赛诺菲的度普利尤单抗自2017年上市后快速放量并持续拓展新适应症，2024年全球销售额超140亿美金。司普奇拜单抗作为全球第二款、国内首款IL-4R单抗，先发优势明显，非头对头比较下疗效较度普利尤单抗更优，目前已经获批三项适应症（AD、CRSwNP、过敏性鼻炎SAR，后两者为独家适应症）。目前司普奇拜单抗已纳入2025年12月国家医保目录，预计26年初执行，进入医保后有望快速放量。自2024年9月上市以来，2024、2025H1销售额分别为0.36亿元、1.69亿元，预计2025-2027年销售额分别有望达3.31/9.05/16.27亿元。CM512（TSLP/IL-13双抗）目前已经进入II期临床，全球进度顺位第二，差异化优势明显，布局呼吸广阔市场，潜力巨大。TSLP和IL-13在哮喘、COPD等多种II型炎症疾病中发挥重要作用，赛诺菲同靶点TSLP/IL-13单抗在I期哮喘中展现出优异的疗效和安全性，公司CM512同为TSLP/IL-13双抗，竞争格局好，I期AD临床显示出较强的疗效和安全性数据，目前正在开展哮喘、COPD、CRSwNP等II期临床，预计或可于2029年获批上市、迭代现有疗法，布局广阔呼吸市场，潜力巨大。CMG901(Claudin 18.2 ADC)已授权AZ，全球进度最快，有望于2026年完成2L胃癌III期临床并申报上市。CMG901为全球进度顺位第二、海外进展最快的Claudin 18.2 ADC，此前已经授权AZ，交易对价包括6300万美元首付款、最高达11.25亿美元潜在里程碑付款及高达低双位数的分层特许权使用费，2L胃癌有望于2026年完成III期并递交NDA，预计2027年或可上市，2026-2027年公司有望获得一定里程碑收入及上市后的低双位数净销售额分成。盈利预测、估值和评级该行预测，2025/2026/2027年公司实现营业收入6.61亿/12.55亿/20.64亿元，同比+54%/+90%/+65%，归母净利润-5.13亿/-2.97亿/2.01亿元，对应EPS为-1.72/-0.99/0.67元。根据DCF估值法，给予目标价83.29港币，首次覆盖，给予“买入”评级。风险提示：销售不及预期风险，研发进度不及预期风险。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2594238125","isCrawlerRequest":true}

国金证券：首次覆盖康诺亚-B(02162)予“买入”评级 目标价83.29港元

精彩评论

国金证券：首次覆盖康诺亚-B(02162)予“买入”评级目标价83.29港元